Restoring Immune Defense
When It Matters Most
Our vision is to deliver immune restoration and drive cures in high-relapse cancers using natural killer (NK) cell therapies.
Genetically Unmodified, Autologous NK Cells
Our NK cells are strategically deployed to do what NO OTHER therapy can.
Watch Video
Restoring Immune Defense
When It Matters Most
Our vision is to deliver immune restoration and drive cures in high-relapse cancers using natural killer (NK) cell therapies.
The Right Therapy.
At The Right Moment.
At NOK Therapeutics, we are developing a genetically unmodified, autologous NK cell therapy – the first cell therapy purpose-built to deepen remissions and drive cures in high-relapse cancers.
We are initially focusing on high-value oncology indications – including multiple myeloma and urothelial cancer – with plans to expand following initial successes.
Why Natural Killer Cells?
NK cells naturally recognize and kill diverse cancer cells, offer a safer profile than T cells, and require no genetic engineering, making them the ideal “clean-up crew” for frail, heavily pre-treated patients.
Why Autologous Natural Killer Cells?
Using the patient’s own NK cells enables lasting persistence without the need for lymphodepletion, removing a major barrier that excludes many patients from cell therapy.
This innovative strategy allows us to deliver a potent cell therapy to patients in ways that are not feasible with other cell therapies.
Old, Frail, Heavily Pre-Treated Patients
Most cell therapies (e.g., CAR-T) require harsh lymphodepletion and carry significant toxicity risks, excluding older, weaker, or heavily pre-treated patients.
Autologous NK cells avoid lymphodepletion and offer a safer profile, enabling treatment in this underserved population.
Repeatable, Outpatient-Friendly Therapy
Unlike one-time, highly complex CAR-T procedures, our NK therapy is amenable to multiple infusions over time.
This enables flexible, outpatient delivery – minimizing patient burden and making durable cell therapy accessible in routine oncology care.
Our Programs
Multiple Myeloma: post-ASCT Consolidation
Post-autologous stem cell transplant (ASCT) multiple myeloma patients face high relapse rates, with limited safe therapeutic options – our NK cell therapy is intended to boost immune recovery, deepen remissions, and drive cures in this setting.
Advanced Bladder Cancer: Combination w/ Avelumab
Despite platinum chemo and avelumab (αPD-L1) maintenance, most advanced bladder cancer patients relapse quickly – creating a clear opportunity for NOK’s NK cells to boost PD-L1 response, extend survival, and drive cures in this setting.
